# Affordable sialoglycans and associated reagents for expanded chemoenzymatic production

> **NIH NIH R42** · INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC. · 2024 · $644,573

## Abstract

Project Summary
Sialoglycans are sialic acid-containing oligosaccharides that play important biological roles in human biology and
pathology and are indispensable molecular probes for research related to bacterial and viral infection, cancer
metastasis, immune regulation, etc. The multifaceted functions of sialoglycans in human milk are also being
explored. Nevertheless, sialoglycan-related research and development of therapeutics and diagnostics have
been hampered by the limited access to these structurally complex compounds as well as the high cost and
special expertise needed for synthesizing and purifying these reagents.
 Among various synthetic strategies for producing sialoglycans, glycosyltransferase-based chemoenzymatic
methods are attractive strategies. An efficient method for synthesizing structurally defined sialoglycans is one-
pot multienzyme (OPME) chemoenzymatic strategy developed by Dr. Hai Yu and Dr. Xi Chen at UC Davis. Each
OPME glycosylation reaction contains a glycosyltransferase and enzymes involved in generating the
corresponding sugar nucleotide donor in situ from a simple monosaccharide. The OPME reactions allow the
synthesis of target glycans containing the desired glycosidic linkage with high regio- and stereo-specificity. At
the current stage, large-scale synthesis by the OPME systems is still limited by the scales and the yields of the
enzymes produced. In addition, OPME reaction conditions can be improved to decrease the amounts of enzymes
used for the synthesis. Product purification processes can also be streamlined using innovative strategies.
 To advance sialic acid-related research and therapeutic development, the goal of this proposed project is to
develop reagents, enzymes, and methods that are ready for commercialization to allow low-cost access to
sialoglycans of high demands and their underlying asialoglycans by the broad scientific community (both
academic and industry) and to enable highly efficient production of diverse biologically important special
sialoglycan targets by even nonspecialists. This will be achieved by the collaboration of the UC Davis team with
IMCS which has expertise in high-yield enzyme production by fermentation, unique lysis technique, commercial
infrastructure to manufacture, and product sale at affordable prices to the community.

## Key facts

- **NIH application ID:** 10909153
- **Project number:** 5R42GM143998-04
- **Recipient organization:** INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC.
- **Principal Investigator:** L. Andrew Lee
- **Activity code:** R42 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $644,573
- **Award type:** 5
- **Project period:** 2021-09-15 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10909153

## Citation

> US National Institutes of Health, RePORTER application 10909153, Affordable sialoglycans and associated reagents for expanded chemoenzymatic production (5R42GM143998-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10909153. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*